Clinical Trial Update: Four Cycles Taxane With Trastuzumab and Pertuzumab Neoadjuvant Therapy Among Low Risk HER2 Positive Patients

View source ↗

Summary

A neoadjuvant trial is evaluating four cycles of a taxane with trastuzumab and pertuzumab in low-risk HER2-positive breast cancer, and the study is currently re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• PACLITAXEL (PACLITAXEL)
• Pertuzumab (pertuzumab)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Shu Wang | Conditions: HER2-positive Breast Cancer | Status: RECRUITING